Zobrazeno 1 - 10
of 1 299
pro vyhledávání: ''
Autor:
Brett H. Herzog, Saiama N. Waqar, Siddhartha Devarakonda, Jeffrey P. Ward, Feng Gao, Ramaswamy Govindan, Daniel Morgensztern
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 173
The treatment options for patients with stage IV non-small cell lung cancer (NSCLC) who develop tumor progression after platinum-based chemotherapy and immune checkpoint inhibitors (ICIs) are limited. The combination of ICI with inhibitors of vascula
Autor:
Chang Liu, Cuicui Liu, Jiatao Liao, Jiani C. Yin, Xianghua Wu, Xinmin Zhao, Si Sun, Huijie Wang, Zhihuang Hu, Yao Zhang, Hui Yu, Yang Shao, Jialei Wang
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 171
Crizotinib remains one of the most commonly used targeted therapies for ALK fusion-positive patients. However, the mutational profiles and mechanisms of resistance to first-line crizotinib treatment remain to be thoroughly examined.We retrospectively
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 166
Asian patients with metastatic non-small cell lung cancer (NSCLC) have a higher prevalence of epidermal growth factor receptor (EGFR) mutations compared to Caucasians, 30-50% and 15%, respectively. Osimertinib is a tyrosine kinase inhibitor approved
Autor:
Mikey B. Lebrett, Emma J. Crosbie, Janelle Yorke, Kath Hewitt, Ailsa Rowlands, Ellena Badrick, D. Gareth Evans, Haval Balata, Richard Booton, Philip A.J. Crosbie
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 168
In England, a risk-based approach is used to determine eligibility for lung cancer screening. Ensuring effective communication and counselling of risk is therefore increasingly important. In this study, we explore the perception of lung cancer risk i
Autor:
Monica Tang, Chee K. Lee, Craig R. Lewis, Michael Boyer, Bernadette Brown, Andrea Schaffer, Sallie-Anne Pearson, Robert J. Simes
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 166
Based on data from randomized controlled trials (RCTs), immune checkpoint inhibitors (ICI) are standard-of-care in advanced non-small cell lung cancer (aNSCLC). However, trial eligibility criteria are restrictive, and participants and outcomes may no
Autor:
Vanathi Sivasubramaniam, Michael Boyer, Rina Hui, Jia Liu, Prunella Blinman, Jenny H. Lee, Nick Pavlakis, Stephen Clarke, Anthony J. Gill, Steven Kao, Winny Varikatt, Wendy A Cooper, Malinda Itchins, Megan B Barnet, Madhawa De Silva, Bo Gao, Alexander E. Davis, Adnan Nagrial, Kenneth Lee
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 155
Predictive biomarkers for poor response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is an area of ongoing research. This multicentre retrospective study sought to determine the impact of programmed death-ligand 1 (PD-
Autor:
Hidetoshi Kasuya, Bierta E. Barfod, Toru Serizawa, Yasunori Sato, Masaaki Yamamoto, Yoshinori Higuchi
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 149
There is little information on stereotactic radiosurgery (SRS) results for brain metastases (BMs) in lung cancer patients ≥75 years of age. We aimed to reappraise whether SRS results for patients ≥75 (very elderly) differ from those of patients w
Autor:
Sylvie Friard, Marie-Ange Massiani, Christos Chouaid, Hélène Doubre, Anne-cecile Metivier, Leila Zemoura, Laure Tabèze, Marie Mayenga, Céline Callens, Elisabeth Longchampt, Jean-Baptiste Assié, Samia Melaabi, Isabelle Monnet, Séverine Fraboulet, Louis-Jean Couderc
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 150
About 2-3% of non-small-cell lung cancers (NSCLCs) harbor MET exon-14-skipping (METex14) mutations. Efficacy of the MET-inhibitor crizotinib has been reported, but progression-free survival (PFS) was very short. Immune-checkpoint inhibitors (ICIs) ha
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 143
Introduction Several obstacles may delay receipt of targeted treatment in patients with anaplastic lymphoma kinase positive (ALK+) non-small-cell lung cancer (NSCLC). This study examined the factors associated with delayed initiation of ALK inhibitor
Autor:
Michael Cabanero, Xuyang Song, Rosalyn A. Juergens, Penelope A. Bradbury, Phillip A. Dennis, John Hilton, P. Brown-Walker, Desiree Hao, John R. Goffin, Sebastien J. Hotte, Anna Tomiak, Gwyn Bebb, Scott A. Laurie, Andrew Robinson, Martin Smoragiewicz, Christian K. Kollmannsberger, I. Gauthier, Moustapha Tehfe, Xiaoqun Sun, Peter M. Ellis, Dongsheng Tu, Paul Wheatley-Price, Mihaela Mates, Janessa Laskin, Glenwood D. Goss, Lesley Seymour, Ming-Sound Tsao
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 143
This multicenter phase Ib study aimed to establish a recommended phase II dose for durvalumab (Du) ± tremelimumab (Tr) in combination with standard platinum-doublet chemotherapy. Eligible patients were enrolled into one of six dose levels (DL) of Du